These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34768018)

  • 61. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection.
    Chang ML; Cheng JS; Chien RN; Liaw YF
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2064-2072.e2. PubMed ID: 31982607
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
    Lim SG; Phyo WW; Ling JZJ; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Huang DQ; Khine HTW; Lee C; Tay A; Chan E
    Aliment Pharmacol Ther; 2021 Jan; 53(1):172-182. PubMed ID: 33159496
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
    Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
    Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers.
    Chang KC; Chang MH; Lee CN; Chang CH; Wu JF; Ni YH; Wen WH; Shyu MK; Lai MW; Chen SM; Hu JJ; Lin HH; Hsu JJ; Mu SC; Lin YC; Liu CJ; Chen DS; Lin LH; Chen HL;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):306-316. PubMed ID: 31271463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
    Urabe A; Imamura M; Tsuge M; Kan H; Fujino H; Fukuhara T; Masaki K; Kobayashi T; Ono A; Nakahara T; Kawaoka T; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Maki N; Ohdan H; Chayama K
    J Gastroenterol; 2017 Mar; 52(3):366-375. PubMed ID: 27422771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan.
    Marusawa H; Osaki Y; Kimura T; Ito K; Yamashita Y; Eguchi T; Kudo M; Yamamoto Y; Kojima H; Seno H; Moriyasu F; Chiba T
    Gut; 1999 Aug; 45(2):284-8. PubMed ID: 10403743
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of HBsAg quantification for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856
    [TBL] [Abstract][Full Text] [Related]  

  • 68. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    ;
    J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Management of chronic hepatitis B infection.
    Sundaram V; Kowdley K
    BMJ; 2015 Oct; 351():h4263. PubMed ID: 26491030
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of treatment response in chronic hepatitis B.
    Wong GL; Chan HL
    Drugs; 2009 Nov; 69(16):2167-77. PubMed ID: 19852523
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
    Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection.
    Zoulim F; Mimms L; Floreani M; Pichoud C; Chemin I; Kay A; Vitvitski L; Trepo C
    J Clin Microbiol; 1992 May; 30(5):1111-9. PubMed ID: 1583107
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
    Chong CC; Wong GL; Lai PB
    World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.
    Ricco G; Popa DC; Cavallone D; Iacob S; Salvati A; Tabacelia D; Oliveri F; Mascolo G; Bonino F; Yuan Q; Xia NS; Gheorghe L; Brunetto MR
    J Viral Hepat; 2018 Aug; 25(8):911-919. PubMed ID: 29577518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.